BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 8, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 15, 2006

View Archived Issues

sanofi-aventis reviews Q4 fortunes

Read More

Preclinical studies evaluate the activity of PPP in multiple myeloma

Read More

Structure analysis reveals binding of JAK2 and JAK inhibitor

Read More

Antiplatelet activity of MRS-2500 observed ex vivo and in vivo

Read More

Patupilone safe, well tolerated in patients with advanced solid tumors

Read More

Medivir acquires Cathepsin S inhibitor project rights from Peptimmune

Read More

New phase I/II study assesses sublingual vaccines with MPL adjuvant for allergy

Read More

Takeda granted rights for Hematide in Japan

Read More

Immtech licenses aminoquinoline drugs from Tulane University

Read More

Vaccinex enters antibody collaboration with Schering AG

Read More

Panvac-VF phase III study completes enrollment

Read More

QR-435 demonstrates antiviral activity against ocular and genital herpes

Read More

Schering AG exercises option for gadofluorine derivative in Epix collaboration

Read More

Cangene awarded funding to develop PEG-GM-CSF for acute radiation syndrome

Read More

Amgen and Biovitrum expand type 2 diabetes and metabolic disease agreement

Read More

Replidyne and Forest enter U.S. agreement for faropenem medoxomil

Read More

Garenoxacin NDA accepted for review

Read More

NCI to study CTCE-9908 for primary effusion lymphoma

Read More

Fast track designation for tesmilifene for advanced breast cancer

Read More

Nalbuphine ER reduces pain intensity in dose-dependent manner

Read More

FDA warns on risks of aprotinin

Read More

DEBIO-025 well tolerated in HIV-1 infected subjects

Read More

MK-0518 active, well tolerated in resistant HIV-1 infection

Read More

TNX-355 targets HIV in a tropism-independent manner

Read More

New N-type calcium channel blockers emerge from Ajinomoto

Read More

Aricept sNDA accepted for review

Read More

AstraZeneca withdraws Exanta

Read More

Novel therapeutics for neurological disorders reported in recent patent literature

Read More

Recent patents impart novel agents for respiratory disorders

Read More

Recent Ono patent reports new coagulation factor Xa inhibitors

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 5, 2026.
  • New York University identifies new analogues of mannose-6-phosphate

    BioWorld Science
    New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
  • Liver disease

    FB-7033 demonstrates efficacy in MASH management

    BioWorld Science
    17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
  • Illustration of antibody carrying radioactive isotope

    Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC

    BioWorld Science
    At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
  • Bial-Portela discovers new OX1 receptor antagonists

    BioWorld Science
    Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing